Wilex AG said that its portfolio of cancer products should reach some important thresholds in 2009. One likely threshold would be the start of a first-in-man trial of a kinase inhibitor which would result in a milestone payment from UCB Pharma SA.
Wilex AG said that its portfolio of cancer products should reach some important thresholds in 2009. One likely threshold would be the start of a first-in-man trial of a kinase inhibitor which would result in a milestone payment from UCB Pharma SA.